spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 19 September 2007
doi: 10.1242/dev.004879

Development 134, 3743-3752 (2007)
Published by The Company of Biologists 2007
This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, A. C.
Right arrow Articles by Ornitz, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, A. C.
Right arrow Articles by Ornitz, D. M.

FGF9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network

Andrew C. White, Kory J. Lavine and David M. Ornitz*

Department of Molecular Biology and Pharmacology, Washington University School of Medicine, 660 S. Euclid Avenue, St Louis, MO 63110, USA.


Figure 1
View larger version (125K):
[in this window]
[in a new window]

  		Fig. 1. FGF9 signaling via mesenchymal FGFR1/2 is necessary and sufficient for distal lung capillary development. (A-F) Whole-mount immunohistochemistry with anti-PECAM antibody showing large gaps between vessels in the distal capillary plexus of Fgf9-/- lungs at E11.5 (B), E12.5 (D) and E13.5 (F) when compared with control lungs (A,C,E). (G,H) Whole-mount lacZ staining with the endothelial cell marker Flk1-lacZ showing a reduction in capillary density around the distal epithelium in Fgf9-/-; Flk1-lacZ+/- lungs at E15.5 (H) compared with control lungs (G). (I,J) Rosa26R-lacZ stain showing endothelial cell-specific Flk1-Cre activity in a pattern consistent with distal lung endothelial cells in whole-mount (I) and frozen (J) sections. (K,L) Fgfr1 and Fgfr2 double conditional knockout using Flk1-Cre (Fgfr1/2Flk; L) showing no difference in distal lung vascular development compared to an Fgfr1/2f/f control (K). (M,N) Fgfr1 and Fgfr2 double conditional knockout using mesenchymal-specific Dermo1-Cre (Fgfr1/2Dermo1), showing reduced distal lung capillary density (N) compared with an Fgfr1/2f/f control (M). (O,P) Induced Fgf9 expression for 48 hours with doxycycline [Fgf9dox(48)] is sufficient to induce Flk1-lacZ expression throughout lung mesenchyme (P), compared with expression only in the sub-epithelial mesenchyme in control lung (O). Histological sections in O and P were photographed through a 20x objective. Scale bars: 50 µm.

 

Figure 2
View larger version (110K):
[in this window]
[in a new window]

  		Fig. 2. Fgf9 is necessary and sufficient for mesenchymal Vegfa expression in the lung. (A-L) Fgf9-/-; Vegfa-lacZ lungs show reduced mesenchymal Vegfa-lacZ staining at E11.5 (B,D), E12.5 (F,H) and E13.5 (J,L) compared with control (A,C,E,G,I,K). At E11.5, no Vegfa is observed in the epithelium (C,D). By E13.5, levels of Vegfa-lacZ in the mesenchyme in Fgf9-/- lungs continue to be reduced compared with controls, but epithelial expression is comparable to controls (K,L). (M-P) Fgf9 overexpression results in increased mesenchymal Vegfa in Fgf9dox(48); Vegfa-lacZ lungs at E13.5 (N,P). Left panels, whole-mount ß-galactosidase staining; right panels, cryosections of left panels. Histology: 20x objective. Scale bars: 100 µm.

 

Figure 3
View larger version (83K):
[in this window]
[in a new window]

  		Fig. 3. FGF9 requires VEGF signaling for the formation and maintenance of the lung capillary network. (A-D) Incubation of E12.5 lung explants for 48 hours with 2.5 ng/µl FGF9 stimulates robust capillary formation (B) compared with untreated lung (A). The VEGFR inhibitor SU5416 (45 µM) eliminates the formation and survival of vessels (C). FGF9 is unable to stimulate growth of new distal vessels in the presence of SU5416 (D) but can partially rescue blood vessel survival in very proximal regions. (E-H) FGF9 stimulates luminal dilation of the epithelial tubules (F). Branching morphogenesis appears comparable to controls in SU5416-treated explants (G). In contrast to capillary development, FGF9-induced luminal dilation is not affected by SU5416 (H). Scale bar: 50 µm.

 

Figure 4
View larger version (126K):
[in this window]
[in a new window]

  		Fig. 4. SHH signaling to non-endothelial mesenchyme is necessary for distal lung capillary formation. (A,B) The Rosa26R allele was used to detect Actin-CreER activation throughout the lung mesenchyme and epithelium at E12.5 following tamoxifen injection at E9.5; (A) whole-mount and (B) frozen sections. (C,D) Conditional knockout of Smo, using Actin-CreER (SmoActin), results in lung hypoplasia (D) compared with a Smof/f control (C) at E12.5. (E,F) When assessed by anti-PECAM whole-mount immunohistochemistry, SmoActin lungs showed a reduction in distal capillary network density (F) compared with Smof/f controls (E) at E12.5. (G,H) Distal lung capillary density appeared similar in Smof/f; Flk1-Cre (SmoFlk1; H) and Smof/f control (G) mice, indicating that HH signaling to endothelial cells is not required for development. (I-L) SmoActin lungs (J,L) show a decrease in VegfA-lacZ activity in mesenchyme distal to the sub-epithelial layer (arrow) in whole-lung preparations (I,J) and frozen sections (K,L) compared with controls. (M-P) Lung organ cultures incubated with 500 ng/ml of SHH-N protein show an increase in PECAM-positive cells (N) and VegfA-lacZ staining (P) compared with BSA-incubated controls (M,O) after 24 hours. (B,K,L) Lower left lobe; (E-J) upper left lobe. Histology: 20x objective. Scale bars: 100 µm.

 

Figure 5
View larger version (146K):
[in this window]
[in a new window]

  		Fig. 5. FGF9 and SHH signaling are both required for capillary formation. E12.5 lung explants from Vegfa-lacZ mice were incubated for 48 hours with media containing BSA (A-C), FGF9 (D-F), cyclopamine (Cy; G-I) or FGF9 and cyclopamine (J-L). (A,D,G,J) Whole-mount anti-PECAM immunohistochemistry showing increased capillary formation in the presence of 2.5 ng/µl FGF9 (D) and decreased vascular development in the presence of 10 µM cyclopamine (G). FGF9 was able to only partially rescue capillary formation in the presence of cyclopamine (J). (B,E,H,K) Whole-mount preparations and (C,F,I,L) frozen sections stained for lacZ activity. Compared with control explants, Vegfa expression is increased in the presence of FGF9 (E,F) and decreased in the presence of cyclopamine (H,I). FGF9 was able to partially rescue Vegfa expression in the presence of cyclopamine (K,L). Notice that, in the presence of cyclopamine, Vegfa expression is retained only in the inner cell layer of the sub-epithelial mesenchyme (arrow in I), but is significantly reduced in the sub-mesothelial mesenchyme (asterisk in I). FGF9 increases Vegfa expression throughout both mesenchymal layers (F), but in the presence of cyclopamine, Vegfa expression is expanded only in the sub-epithelial layer (arrow in L) and remains low in the sub-mesothelial region (asterisk in L). (A-L) Lower left lobe. Histology: 20x objective. Scale bar: 100 µm.

 

Figure 6
View larger version (110K):
[in this window]
[in a new window]

  		Fig. 6. SHH is not sufficient to rescue capillary plexus formation in Fgf9-/- lungs. E11.5 explant cultures of wild-type and Fgf9-/- lungs were incubated with BSA (A,B) or SHH (C,D) for 24 hours. Fgf9-/- lungs (B) formed a less dense capillary plexus compared with wild-type controls (A). In contrast to a wild-type lung (A,C), incubation of Fgf9-/- lungs with SHH did not increase capillary plexus density (D). Scale bar: 50 µm.

 

Figure 7
View larger version (45K):
[in this window]
[in a new window]

  		Fig. 7. Model for the regulation of Vegfa expression during distal lung vascular development by FGF9 and SHH signaling. (1-3) FGF9 signaling via FGFR1 and FGFR2 stimulates SHH signaling (White et al., 2006Go) and Vegfa expression both in sub-mesothelial and sub-epithelial mesenchymal layers. In the absence of SHH signaling, FGF9 has a stronger affect on Vegfa expression in the sub-epithelial compartment (2) compared with the sub-mesothelial compartment (3). (4) Epithelial SHH signals to lung mesenchyme (Bellusci et al., 1997aGo; Weaver et al., 2003Go). SHH signaling is required for Vegfa expression and subsequent vascular development both in sub-mesothelial mesenchyme (5) and sub-epithelial mesenchyme (6; except for the inner-most cell layer, stippled shading). HH signaling to Flk1-Cre+ endothelial cells is not required for capillary development. (7) VEGF is a primary factor regulating vascular growth in the developing lung. Distal capillaries are denoted by red ovals located between sub-mesothelial and sub-epithelial mesenchyme layers.

 




© The Company of Biologists Ltd 2007